ABSTRACT:

Introduction: The mortality rate in persistent kidney disease conditions is progressing gradually. The thirst for early disease identification is quite interesting in the research.
Aim: The current learning is intended to explore the novel association of inflammatory markers with chronic kidney disease (CKD).
Procedures: We conducted this cross-sectional experimental education for three years. We enrolled 400 cases and 50 controls in the education. We obtained knowledgeable consent by grouping all the participants into 4 groups based on the stages of CKD. After completing the biochemical measurements, we used the Enzyme-Linked Immunosorbent Assay (ELISA) to determine the levels of highly sensitive C-reactive protein (hsCRP), Tumor Necrosis Factor Alpha (TNFA), and Interleukine (IL-6). The results were tabulated, statistical analysis was performed and p<0.05 was found to be substantial.
Results: The participants were divided into 54 males and 52 females during the unkind phase. 235 were males, and 165 were females. We found that CKD patients had higher levels of urea and creatinine than the controls. We found TNFA and IL6 to be significant, with P = 0.0001.
Conclusion: Our findings proved novel associations of hCRP, TNFA, and IL6 with Chronic kidney disease.

KEYWORDS :

disease, inflammation, c-reactive protein
.

REFERENCES :

1) Manns B, McKenzie SQ, Au F, et al. The financial impact of advanced kidney disease on Canada pension plan and private disability insurance costs. Can J Kidney Health Dis 2017; 4:205435811770398.
Doi:10.1177/2054358117703986.
2) Collister D, Pannu N. Ye F. “Health care costs associated with AKI,” Clin J Am Soc Nephrol. 2017;12: 1733-1743.doi: 10.2215/CJN.00950117
3) Romagnani G, Remuzzi R, Glassock, et al., “chronic kidney disease,” Nat Rev Dis Prim. 2017 3(1): 17088
doi:10.1038/nrdp.2017.88.
4) Chawla LS, Bellomo R, Bihorac A et al., “Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup,” Nat Rev Nephrol. 2017; 13(4): 241–257. Doi: 10.1038/nrneph.2017.2
5) Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35:469–76.doi:10.1016/s0272-6386(00)70200-9
6) Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000; 101:2149–53.
doi: 10.1161/01.CIR.101.18.2149
7) Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010; 77:550–6.doi:10.1038/ki.2009.503
8) Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012; 7:1938–46. Doi: 10.2215/CJN.03500412
9) Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, O’Donnell CJ, et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant. 2011; 26:920–6.
Doi:10.1161/JAHA.123.0301
10) Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in preventing cardiovascular disease. Circulation. 2001; 103:1813–8. doi: 10.1161/01.CIR.103.13.1813.
11) Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) BMC Nephrol. 2008;9: 9.doi:10.1186/1471-2369-9-9
12) Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004; 140:9–17. Doi:10.7326/0003-4819-140-1-200401060-00006.
13) Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107:87–92
doi: 10.1161/01.CIR.0000042700.48769.59.
14) Sonkar GK, Singh RG. Evaluation of serum tumor necrosis factor alpha and its correlation with histology in chronic kidney disease, stable renal transplant and rejection cases. Saudi J Kidney Dis Transpl. 2009; 20: 1000–1004.
15) Therrien FJ, Agharazii M, Lebel M, Lariviere R. Neutralization of tumor necrosis factor-alpha reduces renal fibrosis and hypertension in rats with renal failure. Am J Nephrol .2012; 36: 151–161.Doi:10.1159/000340033. Epub 2012 Jul 19
16) Yeo ES, Hwang JY, Park JE, Choi YJ, Huh KB, Kim WY. Tumor necrosis factor (TNF-alpha) and C-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. Yonsei Med J 2010; 51: 519–525. Doi:10.3349/ymj.2010.51.4.519
17) Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344–358.doi: 10.1038/nrneph.2017.52.
18) Araújo LS, Torquato BGS, da Silva CA, et al. Renal expression of cytokines and chemokines in diabetic nephropathy. BMC Nephrol. 2020;21(1):308
19) Taslipinar A, Yaman H, Yilmaz MI, et al. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy. Scand J Clin Lab Invest. 2011;71(7):606–612.
Doi:10.3109/00365513.2011.598944.
20) Yacoub R, Habib H, Lahdo A, Al Ali R, Varjabedian L, Atalla G, et al. Association between smoking and chronic kidney disease: a case control study. BMC Public Health. 2010;10(1):1–6.
21) Saucier NA, Sinha MK, Liang KV, Krambeck AE, Weaver AL, Bergstralh EJ, et al. Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis. 2010;55(1):61–68.
Doi: 10.1053/j.ajkd.2009.08.008.
22) Lambert K, Mullan J, Mansfield K, Lonergan M. A cross-sectional comparison of health literacy deficits among patients with chronic kidney disease. J Health Commun. 2015;20(sup2):16–23. Doi:10.1080/10810730.2015.1080329
23) Fraser SD, Roderick PJ, Casey M, Taal MW, Yuen HM, Nutbeam D. Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2013;28(1):129–137. Doi: 10.1093/ndt/gfs371
24) Ji MY, Park YS, Yi SE. A case-control study to identify the risk factors of school accidents. Korean J Epidemiol.
2005;27(2):80–94.
25) Khajehdehi P, Malekmakan L, Pakfetrat M, Roozbeh J, Sayadi M. Prevalence of chronic kidney disease and its contributing risk factors in southern Iran a cross-sectional adult population-based study. 2014.
26) Li H, Lu W, Wang A, Jiang H, Lyu J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from global burden of disease 2017. J Diabetes Investig.
2021;12(3):346. Doi:10.1111/jdi.13355
27) Xu Y, Surapaneni A, Alkas J, Evans M, Shin J-I, Selvin E, et al. Glycemic control and the risk of acute kidney injury in patients with type 2 diabetes and chronic kidney disease: parallel population-based cohort studies in US and Swedish routine care. Diabetes Care. 2020;43(12):2975–2982. Doi:10.2337/dc20-1588. Epub 2020 Oct 6.
28) Sepanlou SG, Barahimi H, Najafi I, Kamangar F, Poustchi H, Shakeri R, et al. Prevalence and determinants of chronic kidney disease in northeast of Iran: results of the Golestan cohort study. PLoS One.
2017;12(5): e017654.doi:10.1371/journal.pone.0176540
29) Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs. 2019;79(4):365–379. Doi:10.1007/s40265-019-1064-1.